Ulrike Köhl

Ulrike Köhl is a full Professor for Immune Oncology at the University of Leipzig, Germany and the director of the Fraunhofer Institute for Cell Therapy and Immunology since 2017 and holds the position of a full Professor and director of the Institute of Cellular Therapeutics at Hannover Medical School since 2012, respectively.

She holds a degree in in biology supplemented by a medicine study. She worked at the MD Anderson Cancer Centre in Houston, USA and at the University Hospital, Frankfurt, Germany. She is an international leading expert in the development and manufacturing of cell and gene therapies in cancer and regenerative medicine and collaborates with both international industry and academic partners. She has a specific own research focus on primary human NK cells as well as chimeric antigen receptor (CAR) expressing T and NK effector cells. The Köhl team has been responsible for one of the first NK cell trial in Europe. Currently, Prof. Köhl is heading “SaxoCell”, a cluster for cell and gene therapy, funded by the Germany federal government as a future and excellence initiative. In addition, she is leading two EU consortia (“Mature-NK” and the IMI “ImSAVAR”). Prof. Köhl is a member of numerous national and international societies and a committee member of scientific advisory boards of different companies.